Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Locke

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Clinical Pharmacology in Drug Development|July 28, 2018
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 StudiesHoi-Kei Lon, Nuno Mendonca, Sandra Goss, et al.
Alcoholism, Clinical and Experimental Research|March 13, 2016
Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol DrinkersDavid A Katz, Charles Locke, Wei Liu, et al.
Journal of Hospital Medicine|February 25, 2015
Recovery Audit Contractor audits and appeals at three academic medical centersAnn M Sheehy, Charles Locke, Jeannine Z Engel, et al.
British Journal of Clinical Pharmacology|July 11, 2012
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skinKlaus Schaffler, Peter Reeh, W Rachel Duan, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly AdultsWei Liu, David A Katz, Charles Locke, et al.
Psychopharmacology|September 9, 2011
The scopolamine model as a pharmacodynamic marker in early drug developmentRobert A Lenz, Jeffrey D Baker, Charles Locke, et al.
Journal of Clinical Pharmacology|July 20, 2005
A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjectsChetan S Karyekar, Rajendra S Pradhan, Tony Freeney, et al.
Microbiology Spectrum|July 10, 2023
Accuracy of Expired BinaxNOW Rapid Antigen TestsMary Jane E Vaeth, Omar Abdullah, Minahil Cheema, et al.
Microbiology Spectrum|February 13, 2024
Self-administered versus clinician-performed BinaxNOW COVID rapid test: a comparison of accuracyMary Jane E Vaeth, Minahil Cheema, Sarah Omer, et al.
Neurobiology of Disease|May 15, 2021
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primatesPeer B Jacobson, Robin Goody, Matthew Lawrence, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Pharmacology in Drug Development|July 28, 2018
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 StudiesHoi-Kei Lon, Nuno Mendonca, Sandra Goss, et al.
Alcoholism, Clinical and Experimental Research|March 13, 2016
Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol DrinkersDavid A Katz, Charles Locke, Wei Liu, et al.
Journal of Hospital Medicine|February 25, 2015
Recovery Audit Contractor audits and appeals at three academic medical centersAnn M Sheehy, Charles Locke, Jeannine Z Engel, et al.
British Journal of Clinical Pharmacology|July 11, 2012
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skinKlaus Schaffler, Peter Reeh, W Rachel Duan, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly AdultsWei Liu, David A Katz, Charles Locke, et al.
Psychopharmacology|September 9, 2011
The scopolamine model as a pharmacodynamic marker in early drug developmentRobert A Lenz, Jeffrey D Baker, Charles Locke, et al.
Journal of Clinical Pharmacology|July 20, 2005
A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjectsChetan S Karyekar, Rajendra S Pradhan, Tony Freeney, et al.
Microbiology Spectrum|July 10, 2023
Accuracy of Expired BinaxNOW Rapid Antigen TestsMary Jane E Vaeth, Omar Abdullah, Minahil Cheema, et al.
Microbiology Spectrum|February 13, 2024
Self-administered versus clinician-performed BinaxNOW COVID rapid test: a comparison of accuracyMary Jane E Vaeth, Minahil Cheema, Sarah Omer, et al.
Neurobiology of Disease|May 15, 2021
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primatesPeer B Jacobson, Robin Goody, Matthew Lawrence, et al.
Pageof 3